Recent advances in managing osteoporosis by Gagnon, Claudia & Ebeling, Peter R
Recent advances in managing osteoporosis
Claudia Gagnon and Peter R Ebeling*
Address: Department of Medicine, University of Melbourne, Western Hospital, Gordon Street, Footscray, 3011, Australia
*Corresponding author: Peter R Ebeling (peterre@unimelb.edu.au)
F1000 Medicine Reports 2009, 1:96 (doi:10.3410/M1-96)
The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/96
Abstract
Osteoporosis is a common disease associated with increased morbidity and mortality. However,
osteoporosis continues to be under-recognized, and the majority of men and women with fractures
go untreated. FRAX
® is a tool that has been developed by the World Health Organization to better
identify people at high absolute risk of fracture. Modalities to assess bone quality, an important
component of bone strength, have also emerged. Combined with new therapeutic options that
promise increased compliance with therapy, the burden of this ever-growing and costly disease may
be reduced.
Introduction and context
Osteoporosis is an under-diagnosed and under-treated
serious disease
From individual and societal perspectives, the conse-
quences of osteoporotic fractures are devastating, being
associated with tremendous costs as well as increased
mortality and morbidity [1-3]. The projected rise in the
prevalence of osteoporosis with the ageing of the
population will likely increase the current burden.
Unfortunately, less than one-third of patients who have
sustained a fragility fracture are diagnosed and treated
for osteoporosis [4]. Among those who have not
yet sustained a fracture but who are at high risk based
on clinical risk factors (CRFs) and bone mineral den-
sity (BMD) measurement, the treatment rate is also
disappointingly low [5].
Limitations of dual-energy X-ray absorptiometry in
identifying individuals at high risk of fracture
Identification by physicians of people at high risk of
fracture is the key step in initiating appropriate treat-
ment. Measurement of BMD at the lumbar spine and
proximal femur by dual-energy X-ray absorptiometry
(DXA) is the current gold standard used to diagnose
osteoporosis, with at least 2.5 standard deviations below
the mean BMD of healthy young adults set as the
threshold (T score ≤-2.5). It is also a good predictor of
fracture risk, with each standard deviation decline in
BMD approximately doubling the fracture risk [6].
However, assessment of fracture risk and the decision
to start treatment should not rely solely on BMD.
Approximately half of fractures occur in people with
osteopenia (T scores of -1.0 to -2.5) or a normal BMD,
highlighting the importance of other factors, such as
age, past history of fragility fracture, bone quality, and so
on, on fracture risk [7]. Failure to identify people at high
risk of fracture could be explained by the low accessi-
bility to DXA machines and the limited time to evaluate
CRFs for fracture in routine practice. Efforts have thus
been made to develop easy-to-use tools (such as FRAX)
that do not necessitate the inclusion of BMD data to
calculate the individual’s absolute risk of fracture [8].
A sD X Am e a s u r e so n l yo n ec o m p o n e n to fb o n e
strength, imaging techniques that evaluate bone quality
are also emerging.
A need for new therapeutic modalities for osteoporosis
Oral bisphosphonates are the cornerstone of osteoporo-
sis treatment, having been on the market for more than a
decade. However, low adherence is a major issue and
concerns about their long-term safety have been raised
[9,10]. Indeed, bisphosphonate use has been associated
with an increased risk of osteonecrosis of the jaw, mainly
in oncology patients receiving high-dose intravenous
Page 1 of 5
(page number not for citation purposes)
© 2009 Medicine Reports Ltd
Published: 15 December 2009
for non-commercial purposes provided the original work is properly cited. You may not use this work for commercial purposes.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License
(http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits unrestricted use, distribution, and reproduction in any medium,bisphosphonate therapy [11]. Atypical subtrochanteric
femoral fractures in patients treated with bisphospho-
nates have also been reported, although results from a
large cohort study suggest that these fractures are more
likely osteoporotic by nature than a complication of
bisphosphonate therapy [12]. Strontium ranelate is
another option for postmenopausal women, but data
in men are lacking. Teriparatide [recombinant human
parathyroid hormone (PTH) (1-34)] and PTH (1-84) are
the only anabolic agents currently available. However,
they are costly and require daily subcutaneous injections.
New options that are likely to enhance adherence to
osteoporosis treatment, namely monthly oral bispho-
sphonate dosing and annual zoledronic acid infusions,
have been released. A novel therapy, subcutaneous
injections of denosumab every 6 months, is imminent.
New antiresorptive and anabolic agents are also in the
early stages of development.
Recent advances
Prediction of absolute risk of fracture using FRAX
FRAX
® is a recently released, web-accessed fracture
assessment tool that has been developed by the World
Health Organization using primary data from nine
population-based cohorts from North America, Europe,
Asia, and Australia and validated in 11 independent
cohorts [8,13]. It allows quick calculation of the 10-year
likelihood of hip and major osteoporotic fractures
(hip, clinical spine, humerus, or wrist fracture) for men
and women between 40 and 90 years of age. The
algorithm uses CRFs, alone or in combination with
femoral neck BMD, to estimate fracture risk. CRFs
included in the model are age, sex, body mass index
calculated from weight and height, history of fragility
fracture (including radiographic vertebral fracture),
parental history of hip fracture, current smoking habits,
current or past use of oral glucocorticoids (prednisolone
≥5 mg daily for at least 3 months), rheumatoid arthritis,
other causes of secondary osteoporosis, and alcohol use
(≥3 units daily). As fracture risk varies worldwide,
selection of a specific country is required. (If a specific
country is not available, the country for which the
epidemiology of osteoporosis most closely approximates
it can be used.)
FRAX is a major advance in systematizing fracture risk
assessment. However, it has a number of limitations that
need to be taken into account when evaluating fracture
risk in an individual [14]. First, dose responses exist for
many CRFs (number of previous fractures, smoking,
alcohol, and glucocorticoids) and need to be weighted
when calculating fracture probabilities. Moreover,
important factors that modulate fracture risk, such as
propensity to fall, increased bone turnover markers
(BTMs), vitamin D deficiency, medications that accel-
erate bone loss (such as aromatase inhibitors and
androgen deprivation therapy), and use of osteoporosis
therapy, are not included in the model. FRAX also does
not consider low spine BMD. Finally, epidemiological
data are lacking for many countries and ethnic groups
outside the US, and data for men are limited.
New imaging techniques for osteoporosis
Given that the majority of vertebral fractures are
asymptomatic and that X-rays are not routinely per-
formed unless symptoms are present, an important
proportion of high-risk individuals may be inadequately
identified and remain untreated for osteoporosis. Ver-
tebral fracture assessment by DXA (VFA-DXA) involves
minimal radiation exposure and is a convenient low-cost
screening procedure that has been shown to adequately
detect moderate to severe vertebral fractures in older
women as compared with conventional X-rays [15].
However, reimbursement of VFA-DXA is still not
uniformly available worldwide.
BMD measurement by DXA evaluates only one determi-
nant of bone strength. Imaging techniques such as high-
resolution peripheral computed tomography, three-
dimensional micro-computed tomography, and micro-
magnetic resonance imaging assess other bone strength
components such as trabecular and cortical bone
microarchitecture and could enhance the detection of
people at high risk of fracture [16]. However, at present,
the lack of normative data and the high cost and
low availability of these modalities preclude its use in
clinical practice.
Vertebroplasty for painful vertebral fractures
Findings from two recent methodologically rigorous
Australian and international randomized placebo-con-
trolled trials of vertebroplasty for painful acute vertebral
fractures show, for the first time, that vertebroplasty is no
better than a sham procedure in reducing pain for up to
6 months after an acute vertebral fracture [17,18]. The
safety of vertebroplasty will also be assessed in longer-
term follow-up of patients enrolled in the current
studies.
Novel therapies for osteoporosis
Risedronate 150 mg once a month was approved by the
US Food and Drug Administration (FDA) in 2008 for the
treatment of postmenopausal osteoporosis. In a non-
inferiority trial comparing risedronate 150 mg monthly
with risedronate 5 mg daily, similar increases in BMD at
the lumbar spine and hip, decreases in BTMs, and
reductions in the incidence of radiologic vertebral
fractures were seen at 1 year [19].
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major addition to the armamentarium of osteoporosis
treatment, being both effective and requiring annual
intravenous infusions, thus eliminating some drawbacks
of oral bisphosphonate therapy. Zoledronic acid has
been shown to reduce vertebral and non-vertebral
fractures by 70% and 25%, respectively, as well as hip
fractures by 41%, over 3 years in postmenopausal
women [20]. This is also the only medication to date
to reduce all-cause mortality by 28% and all clinical
fractures by 35% in older men and women who received
zoledronic acid 5 mg versus placebo within 3 months
of sustaining a hip fracture [21]. Recently, a single
zoledronic acid infusion was reported to be non-inferior
and possibly superior to daily oral risedronate in the
prevention and treatment of glucocorticoid-induced
bone loss [22]. Furthermore, the 36-month interim
results of the Zometa-Femara Adjuvant Synergy Trial
(Z-FAST) suggest that up-front zoledronic acid at a dose
of 4 mg every 6 months is more effective in preventing
aromatase inhibitor-associated bone loss than delaying
treatment until bone loss or a fracture has occurred in
women with breast cancer [23]. Of interest, the effects of
a single zoledronic acid infusion on BMD and BTMs have
been shown to persist for at least 2 years, suggesting that
a greater interval between infusions could possibly
maintain its anti-fracture efficacy in patients with
osteoporosis [24].
Novel osteoporosis therapies are also going through the
final steps of approval and should become available
shortly. Denosumab is a human antibody to RANKL
(receptor activator of nuclear factor-kappa-B ligand), an
inhibitor of osteoclast differentiation, proliferation, and
function. Phase II and phase III clinical trials of
denosumab in the treatment and prevention of post-
menopausal osteoporosis and the treatment and pre-
vention of bone loss in patients undergoing hormone
ablation for prostate or breast cancer have been
performed. Denosumab is administered subcutaneously
at a dose of 60 mg every 6 months in the treatment of
postmenopausal osteoporosis. It reduced the 3-year
incidence of new vertebral, non-vertebral, and hip
fractures in postmenopausal women with osteoporosis
by 68%, 20%, and 40%, respectively, compared with
placebo [25]. Treatment with denosumab also resulted
in greater increases in BMD and reductions in BTMs than
alendronate [26]. In men with non-metastatic prostate
cancer undergoing androgen deprivation therapy, BMD
increased and the risk of new vertebral fractures was
decreased by 62% after 3 years of denosumab versus
placebo [27]. Novel SERMs (selective estrogen receptor
modulators) (e.g., lasofoxifene) are also in development.
Lasofoxifene at a dose of 0.5 mg/day has been shown to
decrease vertebral and non-vertebral fractures by 42%
and 22%, respectively, as well as the risk of estrogen-
positive breast cancer by 67%, in postmenopausal
women [28].
Briefly, new anti-resorptive and anabolic agents are also
in the early stages of clinical development. Cathepsin K
is an enzyme present in osteoclasts and is necessary
for bone matrix degradation during bone resorption.
A 2-year course of 50 mg of oral weekly odanacatib, a
selective inhibitor of cathepsin K, increased lumbar spine
and total hip BMDs by 5.5% and 3.2%, respectively,
while the BTMs urinary N-telopeptide and bone-specific
alkaline phosphatase decreased by 52% and 13%,
respectively [29]. Our improved understanding of the
molecular pathways involved in bone formation has led
to the identification of new anabolic therapeutic targets.
For example, activation of the Wnt signaling pathway has
been shown to promote bone formation. Association of
Wnt proteins with the membrane receptors Frizzled and
LRP5/6 (low-density-lipoprotein (LDP) receptor-related
proteins 5 and 6) results in the accumulation of b-
catenin, a molecule important for the transcription of
genes involved in bone formation, through the disrup-
tion of a protein complex (comprising glycogen synthase
kinase 3), responsible for phosphorylation and degrada-
tion of b-catenin. Blockade of natural antagonists of the
Wnt pathway such as sclerostin, the SOST (sclerosteosis)
gene product secreted by osteocytes, and Dickkopf
(Dkk)-1 could potentially lead to new anabolic drugs.
Preclinical studies of anti-sclerostin antibody treatment
in a rat model of postmenopausal osteoporosis showed
promise as a potential anabolic agent by increasing bone
formation, bone mass, and bone strength [30]. A single
subcutaneous dose of sclerostin antibody administered
to healthy postmenopausal women resulted in a mean
increase in the bone formation marker serum P1NP by
60-100% at 21 days and a trend of decrease in the
bone resorption marker serum C-telopeptide [31].
Finally, targeting the calcium-sensing receptor in para-
thyroid or bone cells is also a potential way of treating
osteoporosis [32].
Implications for clinical practice
FRAX is a quick accessible tool that uses readily available
CRFs, without necessitating BMD data, to calculate 10-
year absolute probabilities of fracture. When used
properly, it provides valuable and meaningful informa-
tion to both clinicians and patients. Given the limita-
tions of FRAX, clinical judgement is required when
interpreting the results. The ultimate application of
FRAX is to identify high-risk individuals who would be
candidates for therapy, especially those in the osteopenic
range. Treatment guidelines based on expert opinions or
Page 3 of 5
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:96 http://F1000.com/Reports/Medicine/content/1/96cost-effectiveness analyses are emerging, using thresh-
olds of FRAX-calculated 10-year fracture probabilities of
hip and major osteoporotic fractures for intervention
[33-35]. It is likely that FRAX will be incorporated into
the reporting software for bone densitometry.
Low adherence and persistence with daily and weekly
oral bisphosphonates have a great impact on anti-
fracture efficacy [36]. Whether the availability of less
frequent oral and intravenous regimens will improve
persistence with treatment is yet to be determined. Cost,
potential side effects, and contraindications are also
important factors that restrain treatment options in some
patients. Novel anti-resorptive and anabolic therapies are
being developed as alternatives for patients with
osteoporosis.
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